Aprotinin inhibits SARS-CoV-2 replication
October 2020
Goethe University, Frankfurt, Germany(1)
University of Kent, Canterbury, United Kingdom(2)
University of Kent, Canterbury, United Kingdom(2)
In order for the SARS-CoV-2 virus to enter host cells, its spike protein has to be cleaved by the cell’s own enzymes - proteases. Using multiple human cell types and multi-omics approaches, the study shows that the protease inhibitor aprotinin can prevent cell infection. An aprotinin aerosol is already approved in Russia for the treatment of influenza and could readily be tested for the treatment of COVID-19.
Aprotinin inhibits SARS-CoV-2 replication
Jindrich Cinatl (1), Mark N. Wass(2), Martin Michaelis(2)
Added on: 12-18-2020
[1] https://www.mdpi.com/2073-4409/9/11/2377/htm[2] https://www.bionity.com/en/news/1168817/the-drug-aprotinin-inhibits-entry-of-sars-cov2-in-host-cells.html
